Novel D-form of hybrid peptide (D-AP19) rapidly kills Acinetobacter baumannii while tolerating proteolytic enzymes.

Phanvimon Jariyarattanarach, Natthaporn Klubthawee, Mathira Wongchai, Sittiruk Roytrakul, Ratchaneewan Aunpad
Author Information
  1. Phanvimon Jariyarattanarach: Graduate Program in Biomedical Sciences, Faculty of Allied Health Sciences, Thammasat University, Khlong Luang, Pathum Thani, 12120, Thailand.
  2. Natthaporn Klubthawee: Graduate Program in Biomedical Sciences, Faculty of Allied Health Sciences, Thammasat University, Khlong Luang, Pathum Thani, 12120, Thailand.
  3. Mathira Wongchai: Graduate Program in Biomedical Sciences, Faculty of Allied Health Sciences, Thammasat University, Khlong Luang, Pathum Thani, 12120, Thailand.
  4. Sittiruk Roytrakul: Functional Ingredients and Food Innovation Research Group, National Center for Genetic Engineering and Biotechnology, National Science and Technology Development Agency, Khlong Luang, Pathum Thani, 12120, Thailand.
  5. Ratchaneewan Aunpad: Graduate Program in Biomedical Sciences, Faculty of Allied Health Sciences, Thammasat University, Khlong Luang, Pathum Thani, 12120, Thailand. aratchan@tu.ac.th.

Abstract

Antimicrobial peptides (AMPs) are being developed as potent alternative treatments to conventional antibiotics which are unlikely to induce bacterial resistance. They can be designed and modified to possess several druggable properties. We report herein a novel hybrid peptide of modified aurein (A3) and cathelicidin (P7), or A3P7, by a flipping technique. It exhibited potent antibacterial activity against both Gram-negative and -positive pathogenic bacteria but had moderate hemolytic activity. To reduce the sequence length and toxicity, C-terminal truncation was serially performed and eight truncated derivatives (AP12-AP19) were obtained. They had significantly less hemolytic activity while preserving antibacterial activity. Secondary structures of the candidate peptides in environments simulating bacterial membranes (30 mM SDS and 50% TFE), determined by CD spectroscopy, showed α-helical structures consistent with predicted in silico 3D structural models. Among the peptides, AP19 demonstrated the best combination of broad-spectrum antibacterial activity (including toward Acinetobacter baumannii) and minimal hemolytic and cytotoxic activities. A D-form peptide (D-AP19), in which all L-enantiomers were substituted with the D-enantiomers, maintained antibacterial activity in the presence of pepsin, trypsin, proteinase K and human plasma. Both isomers exhibited potent antibacterial activity against multi-drug (MDR) and extensively-drug resistant (XDR) clinical isolates of A. baumannii comparable to the traditional antibiotic, meropenem. D-AP19 displayed rapid killing via membrane disruption and leakage of intracellular contents. Additionally, it showed a low tendency to induce bacterial resistance. Our work suggested that D-AP19 could be further optimized and developed as a novel compound potentially for fighting against MDR or XDR A. baumannii.

References

  1. Sci Rep. 2020 Jun 4;10(1):9117 [PMID: 32499514]
  2. Clin Infect Dis. 2010 Jul 1;51(1):79-84 [PMID: 20504234]
  3. Acc Chem Res. 2019 Mar 19;52(3):749-759 [PMID: 30829472]
  4. Appl Microbiol Biotechnol. 2016 Nov;100(21):9125-9132 [PMID: 27241023]
  5. Biochem Biophys Res Commun. 2019 Jun 25;514(2):497-502 [PMID: 31056261]
  6. Sci Rep. 2020 Aug 6;10(1):13206 [PMID: 32764602]
  7. J Photochem Photobiol B. 2019 Nov;200:111645 [PMID: 31671371]
  8. ChemMedChem. 2021 Jan 19;16(2):355-367 [PMID: 33026188]
  9. Peptides. 2012 Oct;37(2):207-15 [PMID: 22800692]
  10. AMB Express. 2019 Jul 30;9(1):122 [PMID: 31363941]
  11. Biomolecules. 2018 Jan 19;8(1): [PMID: 29351202]
  12. Nat Commun. 2020 Jun 23;11(1):3184 [PMID: 32576824]
  13. Life (Basel). 2021 Jun 23;11(7): [PMID: 34201519]
  14. Sci Rep. 2016 Jun 08;6:27394 [PMID: 27271216]
  15. Antimicrob Agents Chemother. 2012 Jun;56(6):3298-308 [PMID: 22430978]
  16. Biomaterials. 2013 Jan;34(1):237-50 [PMID: 23046754]
  17. Clin Infect Dis. 2013 May;56(9):1310-8 [PMID: 23334810]
  18. Nat Rev Drug Discov. 2012 Oct;11(10):751-61 [PMID: 22935759]
  19. Antimicrob Agents Chemother. 2002 Dec;46(12):3883-91 [PMID: 12435692]
  20. Front Microbiol. 2019 Apr 12;10:795 [PMID: 31031739]
  21. Antimicrob Agents Chemother. 2002 Nov;46(11):3585-90 [PMID: 12384369]
  22. Biochim Biophys Acta Biomembr. 2020 Jun 1;1862(6):183262 [PMID: 32147356]
  23. Biomol Concepts. 2016 Jun 1;7(3):179-87 [PMID: 27159920]
  24. Biomed Res Int. 2014;2014:867381 [PMID: 25243191]
  25. Sci Rep. 2017 Jul 31;7(1):6953 [PMID: 28761101]
  26. PLoS One. 2014 Jan 21;9(1):e86364 [PMID: 24466055]
  27. Crit Rev Biotechnol. 2012 Jun;32(2):143-71 [PMID: 22074402]
  28. Front Neurosci. 2017 Feb 14;11:73 [PMID: 28261050]
  29. Biomaterials. 2015 Jun;52:517-30 [PMID: 25818457]
  30. Protein Cell. 2010 Feb;1(2):143-52 [PMID: 21203984]
  31. Pathog Dis. 2018 Oct 1;76(7): [PMID: 30184071]
  32. Protein Cell. 2014;5(8):631-42 [PMID: 24805306]
  33. Sci Rep. 2020 Feb 27;10(1):3580 [PMID: 32107445]
  34. Int J Mol Sci. 2020 Aug 27;21(17): [PMID: 32867384]
  35. Mil Med Res. 2021 Sep 9;8(1):48 [PMID: 34496967]
  36. Can J Microbiol. 2021 Feb;67(2):119-137 [PMID: 32783775]
  37. Int J Antimicrob Agents. 2021 Apr;57(4):106324 [PMID: 33746045]
  38. PLoS One. 2014 Jun 19;9(6):e98935 [PMID: 24945359]
  39. Peptides. 2005 Dec;26(12):2368-76 [PMID: 15939509]
  40. Med Res Rev. 2019 May;39(3):831-859 [PMID: 30353555]
  41. Antimicrob Agents Chemother. 2007 Apr;51(4):1398-406 [PMID: 17158938]
  42. Front Microbiol. 2020 Nov 25;11:569118 [PMID: 33324358]
  43. Nat Rev Drug Discov. 2020 May;19(5):311-332 [PMID: 32107480]
  44. PLoS One. 2019 May 9;14(5):e0216669 [PMID: 31071184]
  45. Proc Natl Acad Sci U S A. 2019 Dec 26;116(52):26516-26522 [PMID: 31843919]
  46. Eur J Med Chem. 2015 Aug 28;101:34-40 [PMID: 26114809]

MeSH Term

Humans
Acinetobacter baumannii
Anti-Bacterial Agents
Bacteria
Drug Resistance, Multiple, Bacterial
Endopeptidase K
Meropenem
Microbial Sensitivity Tests
Pepsin A
Peptide Hydrolases
Trypsin

Chemicals

Anti-Bacterial Agents
Endopeptidase K
Meropenem
Pepsin A
Peptide Hydrolases
Trypsin

Word Cloud

Created with Highcharts 10.0.0activityantibacterialbaumanniiD-AP19peptidespotentbacterialpeptidehemolyticdevelopedinduceresistancemodifiednovelhybridexhibitedstructuresshowedAcinetobacterD-formMDRXDRAntimicrobialAMPsalternativetreatmentsconventionalantibioticsunlikelycandesignedpossessseveraldruggablepropertiesreporthereinaureinA3cathelicidinP7A3P7flippingtechniqueGram-negative-positivepathogenicbacteriamoderatereducesequencelengthtoxicityC-terminaltruncationseriallyperformedeighttruncatedderivativesAP12-AP19obtainedsignificantlylesspreservingSecondarycandidateenvironmentssimulatingmembranes30 mMSDS50%TFEdeterminedCDspectroscopyα-helicalconsistentpredictedsilico3DstructuralmodelsAmongAP19demonstratedbestcombinationbroad-spectrumincludingtowardminimalcytotoxicactivitiesL-enantiomerssubstitutedD-enantiomersmaintainedpresencepepsintrypsinproteinaseKhumanplasmaisomersmulti-drugextensively-drugresistantclinicalisolatescomparabletraditionalantibioticmeropenemdisplayedrapidkillingviamembranedisruptionleakageintracellularcontentsAdditionallylowtendencyworksuggestedoptimizedcompoundpotentiallyfightingNovelrapidlykillstoleratingproteolyticenzymes

Similar Articles

Cited By